Literature DB >> 33536537

Iron accumulation in the oculomotor nerve of the progressive supranuclear palsy brain.

Hansol Lee1, Myung Jun Lee2, Eun-Joo Kim2, Gi Yeong Huh3, Jae-Hyeok Lee4, HyungJoon Cho5.   

Abstract

Abnormal iron accumulation around the substantia nigra (SN) is a diagnostic indicator of Parkinsonism. This study aimed to identify iron-related microarchitectural changes around the SN of brains with progressive supranuclear palsy (PSP) via postmortem validations and in vivo magnetic resonance imaging (MRI). 7 T high-resolution MRI was applied to two postmortem brain tissues, from one normal brain and one PSP brain. Histopathological examinations were performed to demonstrate the molecular origin of the high-resolution postmortem MRI findings, by using ferric iron staining, myelin staining, and two-dimensional laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS) imaging. In vivo iron-related MRI was performed on five healthy controls, five patients with Parkinson's disease (PD), and five patients with PSP. In the postmortem examination, excessive iron deposition along the myelinated fiber at the anterior SN and third cranial nerve (oculomotor nerve) fascicles of the PSP brain was verified by LA-ICP-MS. This region corresponded to those with high R2* values and positive susceptibility from quantitative susceptibility mapping (QSM), but was less sensitive in Perls' Prussian blue staining. In in vivo susceptibility-weighted imaging, hypointense pixels were observed in the region between the SN and red nucleus (RN) in patients with PSP, but not in healthy controls and patients with PD. R2* and QSM values of such region were significantly higher in patients with PSP compared to those in healthy controls and patients with PD as well (vs. healthy control: p = 0.008; vs. PD: p = 0.008). Thus, excessive iron accumulation along the myelinated fibers at the anterior SN and oculomotor nerve fascicles may be a pathological characteristic and crucial MR biomarker in a brain with PSP.

Entities:  

Year:  2021        PMID: 33536537      PMCID: PMC7859181          DOI: 10.1038/s41598-021-82469-w

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  40 in total

1.  Human brain myelination and amyloid beta deposition in Alzheimer's disease.

Authors:  George Bartzokis; Po H Lu; Jim Mintz
Journal:  Alzheimers Dement       Date:  2007-04       Impact factor: 21.566

Review 2.  The role of iron in brain ageing and neurodegenerative disorders.

Authors:  Roberta J Ward; Fabio A Zucca; Jeff H Duyn; Robert R Crichton; Luigi Zecca
Journal:  Lancet Neurol       Date:  2014-10       Impact factor: 44.182

3.  MRI T2 and T2* relaxometry to visualize neuromelanin in the dorsal substantia nigra pars compacta.

Authors:  Hansol Lee; Sun-Yong Baek; Eun-Joo Kim; Gi Yeong Huh; Jae-Hyeok Lee; HyungJoon Cho
Journal:  Neuroimage       Date:  2020-02-11       Impact factor: 6.556

4.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

5.  Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes.

Authors:  Mechelle M Lewis; Guangwei Du; Jennifer Baccon; Amanda M Snyder; Ben Murie; Felicia Cooper; Christy Stetter; Lan Kong; Christopher Sica; Richard B Mailman; James R Connor; Xuemei Huang
Journal:  Mov Disord       Date:  2018-05-14       Impact factor: 10.338

Review 6.  Eyelid motor abnormalities in progressive supranuclear palsy.

Authors:  F Grandas; A Esteban
Journal:  J Neural Transm Suppl       Date:  1994

Review 7.  Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease.

Authors:  Fabio A Zucca; Juan Segura-Aguilar; Emanuele Ferrari; Patricia Muñoz; Irmgard Paris; David Sulzer; Tadeusz Sarna; Luigi Casella; Luigi Zecca
Journal:  Prog Neurobiol       Date:  2015-10-09       Impact factor: 11.685

Review 8.  Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics.

Authors:  Abdel A Belaidi; Ashley I Bush
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

9.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.

Authors:  D T Dexter; A Carayon; F Javoy-Agid; Y Agid; F R Wells; S E Daniel; A J Lees; P Jenner; C D Marsden
Journal:  Brain       Date:  1991-08       Impact factor: 13.501

10.  9.4 T MR microscopy of the substantia nigra with pathological validation in controls and disease.

Authors:  L A Massey; M A Miranda; O Al-Helli; H G Parkes; J S Thornton; P-W So; M J White; L Mancini; C Strand; J Holton; A J Lees; T Revesz; T A Yousry
Journal:  Neuroimage Clin       Date:  2016-11-17       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.